<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./617.新药申请 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app227.us.archive.org';v.server_ms=153;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./617.新药申请 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./617.新药申请 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d10617.htm","20221025182750","https://web.archive.org/","web","/_static/",
	      "1666722470");
</script>
<link rel="stylesheet" type="text/css" href="./617.新药申请 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./617.新药申请 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="新药申请 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025182750/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221025182750im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./617.新药申请 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./617.新药申请 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./617.新药申请 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./617.新药申请 - 搜狗科学百科_files/highlight.min.css"><title>新药申请 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221025193758/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style></head><body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d10617.htm","20221025182750",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('29fe447cd1bd4360ac96186057cd282c') window._gtag.traceId = '29fe447cd1bd4360ac96186057cd282c';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221025182750/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221025182750/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221025182750/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221025182750/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221025182750/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221025182750/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221025182750/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221025182750/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221025182750/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>新药申请</h1><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="14995430764970259"><div class="text_img ed_imgfloat_right"><a class="ed_image_link" data-src="https://img04.sogoucdn.com/app/a/200698/sogou_science_13374" data-bigsrc="https://img04.sogoucdn.com/app/a/200698/sogou_science_13374?w=300&amp;h=228&amp;titlename=20%E4%B8%96%E7%BA%AA30%E5%B9%B4%E4%BB%A3%E6%96%B0%E8%8D%AF%E7%A3%BA%E8%83%BA%E5%90%A1%E5%95%B6%E5%9C%A8%E7%BE%8E%E5%9B%BD%E9%A3%9F%E5%93%81%E8%8D%AF%E5%93%81%E7%9B%91%E7%9D%A3%E7%AE%A1%E7%90%86%E5%B1%80%E7%9A%84%E7%94%B3%E8%AF%B7" title="点击查看大图" data-w="300" data-h="228" style="background-image:url(https://web.archive.org/web/20221025182750im_/https://img04.sogoucdn.com/app/a/200698/sogou_science_13374)" href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#!"></a><div class="text_img_title">20世纪30年代新药磺胺吡啶在美国食品药品监督管理局的申请</div></div><div><p></p> 
<p>美国食品药品监督管理局（FDA）的新药申请(NDA)是药物研发人员向FDA正式提出批准某种新药上市销售的重要环节。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_2" class="kx_ref">[2]</a></sup> 如果成功的话，只有大约30%或更少的初始候选药物在通过多年的药物研发后最终获得NDA批准。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_1" class="kx_ref">[1]</a></sup> </p>
<p>NDA的目的是提供足够的信息来确保FDA的审查人员能够建立候选药物的完整发展史。申请所需的材料包括:<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_2" class="kx_ref">[2]</a></sup> </p> 
<ul>
 <li>专利和生产信息</li> 
 <li>按照说明书使用时的药物安全性及其指定用途的特定疗效</li> 
 <li>机构审查委员会完成的临床试验设计、合规性和结果报告</li> 
 <li>药物滥用的易感性</li> 
 <li>指定标签(包装说明书)和使用说明</li>
</ul> 
<p>这一过程除了某些州选民提出的“药用大麻”的倡议<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_3" class="kx_ref">[3]</a></sup>。 </p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col1"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14995430764970260">试验前</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14995430764970261">临床试验</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14995430781747464">实际应用</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14995430781747465">对类似产品的要求</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14995430764970260"><h2 class="title">1 试验前<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>在美国，为了对人体受试者进行药物的合法测试，制造商必须首先从FDA获得研究新药（IND）的指示。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_4" class="kx_ref">[4]</a></sup> 该申请基于非临床数据，通常来自实验室体内体外相结合的安全性研究，来表明该药物在人体实验中足够安全。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_4" class="kx_ref">[4]</a></sup> 提交审批的“新”药物通常包括新分子实体<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_5" class="kx_ref">[5]</a></sup>或经过化学修饰产生不同药理作用或减少副作用的原药物。 </p></div></div><div id="par_14995430764970261"><h2 class="title">2 临床试验<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>药物批准的法律要求是通过临床对照试验证明药物有效性的“实体”证据。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_6" class="kx_ref">[6]</a></sup>该标准是药品监管的核心。提交的数据必须来自严格的临床试验。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_4" class="kx_ref">[4]</a></sup> </p>
<p>试验通常分三个阶段进行:<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_4" class="kx_ref">[4]</a></sup> </p> 
<ul>
 <li>第一阶段:在20到100名健康志愿者中测试该药物，以确定药物在低剂量下的安全性。大约70%的候选药物进入第二阶段。</li> 
 <li>第二阶段:在多达数百名针对该疾病的患者中测试该药物的疗效和安全性。大约三分之二的候选药物由于未达到预期疗效而在第二阶段的临床试验中被淘汰。</li> 
 <li>第三阶段:在双盲试验、安慰剂对照试验中，该药物通常在数百至数千名针对该疾病的患者中进行试验，以证明其特定疗效。不到30%的候选药物成功通过第三阶段。</li> 
 <li>第四阶段:这些是在数千名服用该药物的人群中进行的药物上市后监测试验，目的是为了监测批准上市药物的药物疗效和安全性。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_4" class="kx_ref">[4]</a></sup></li>
</ul> 
<p>针对药物安全性和有效性的法律要求被解读为需要科学的证据来证明药物的利大于弊，并且要有详细的使用说明，因为许多药物具有副作用。 </p>
<p>许多用于治疗严重疾病(例如癌症)的批准药物都有严重甚至危及生命的副作用。即使是相对安全且熟知的非处方药，例如阿司匹林，如果使用不当也会有危险。 </p></div></div><div id="par_14995430781747464"><h2 class="title">3 实际应用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>试验的结果将被编入FDA批准的公共文件，命名为产品标签、包装说明书或完整的处方信息。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_7" class="kx_ref">[7]</a></sup> 处方信息可以从FDA、药品制造商的网站上获取，<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_8" class="kx_ref">[8]</a></sup>并印于药品包装。药品标签的主要目的是为医疗保健提供者提供安全使用该药物的相关信息和指导。 </p>
<p>NDA要求的文件要能说明药物的全部情况，包括临床试验期间发生的情况、药物配方组成、动物研究结果、药物在体内的作用以及公司制造、加工和包装药物的过程。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_2" class="kx_ref">[2]</a></sup>目前，FDA的决策过程缺乏透明度，但是，FDA正在努力使新药的效益风险评估标准化。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_9" class="kx_ref">[9]</a></sup>一旦获得NDA的批准，新药从获批那天起即可在美国合法上市 </p>
<p>在2009年提交的初始NDA文件中，131份文件中有94份(72%)是eCTD格式。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_10" class="kx_ref">[10]</a></sup> </p>
<p>一旦提交申请，FDA会进行60天的初步审查，来评估NDA是否“可以通过实质性审查”。如果FDA发现NDA无法通过(理由可以是从申请中的简单行政错误到要求重新进行测试)，那么FDA会向申请人发送拒绝信函拒绝其申请，该信函解释了为何申请不符合要求。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_11" class="kx_ref">[11]</a></sup> </p>
<p>假设FDA认为可以通过，他们将决定NDA是需要标准审查还是加速审查，并在另一封被称为74天信函的信件中传达对该申请的接受以及他们的审查选择。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_12" class="kx_ref">[12]</a></sup> 标准审查意味着FDA会在大约10个月内完成，而优先审查会在6个月内完成。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_13" class="kx_ref">[13]</a></sup>该决定来自一封完全回应函。 </p></div></div><div id="par_14995430781747465"><h2 class="title">4 对类似产品的要求<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>生物制剂，例如疫苗和许多用于医疗的重组蛋白，通常是由FDA通过生物制品许可申请(BLA)批准，而不是通过NDA批准。生物制剂的生产与简单的化学制剂生产完全不同，批准程序略微不同。 </p>
<p>由另一制造商通过NDA提交的仿制药通过简略新药申请(ANDA)获得批准，该药不必进行NDA中新药所需的所有临床试验。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_14" class="kx_ref">[14]</a></sup> 根据美国现行法律，大多数生物药物，包括大多数的重组蛋白，并不符合ANDA的要求。<sup><a href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/d10617.htm#quote_15" class="kx_ref">[15]</a></sup>然而，有些生物药物，包括生物合成胰岛素、生长激素、胰高血糖素、降钙素和透明质酸酶，在《联邦食品药品和化妆品法案》的管理下不受限制，因为这些产品在后来《公共卫生服务法案》的生物技术药品法规中已经获得批准。 </p>
<p>打算用于动物的药物将提交至FDA的另一个中心，即新兽药申请的兽医中心(CVM)。还专门评估了药物在食用动物中的使用以及它们对采用药物治疗的动物进食所产生的影响。 </p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The Drug Development Process". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The Drug Development Process. Step 4: FDA Drug Review". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Commissioner, Office of the. "Public Health Focus - FDA and Marijuana". www.fda.gov. Archived from the original on April 28, 2018. Retrieved April 30, 2018..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The Drug Development Process. Step 3: Clinical Research". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"The Drug Development Process. Step 1: Discovery and Development". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Food, Drug, and Cosmetic Act, Section 505; 21 USC 355].</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">21 CFR 201.5: Labeling Requirements for Prescription Drugs and/or Insulin.</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Daily Med:Current Medication Information". Archived from the original on November 12, 2008. Retrieved October 10, 2007..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Liberti L, McAuslane JN, Walker S (2011). "Standardizing the Benefit-Risk Assessment of New Medicines: Practical Applications of Frameworks for the Pharmaceutical Healthcare Professional". Pharm Med. 25 (3): 139–46. doi:10.1007/BF03256855. Archived from the original on February 6, 2012..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kathie Clark (December 15, 2009). "Updates from the Regulators:FDA". The eCTD summit. Archived from the original on July 16, 2011..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Merck KGaA Receives Refuse To File Letter From FDA On Cladribine Tablets New Drug Application". medicalnewstoday.com. Archived from the original on March 5, 2010. Retrieved April 30, 2018..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Archived copy". Archived from the original on March 8, 2010. Retrieved February 23, 2010.CS1 maint: Archived copy as title (link).</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance for Treatment of Acute Pain and Fever". drugs.com. Archived from the original on July 11, 2017. Retrieved April 30, 2018..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"FDA, CDER Office of Generic Drugs". fda.gov. Archived from the original on May 28, 2009. Retrieved April 30, 2018..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"C&amp;EN: COVER STORY - BEYOND HATCH-WAXMAN". pubs.acs.org. Retrieved April 30, 2018..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->158</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221025182750/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221025182750/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221025182750/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221025182750/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"10617","versionId":"14995430832079363","title":"新药申请","subtitle":"","abstracts":{"paragraphId":"14995430764970259","title":"简介","versionId":"14995430832079364","lemmaId":10617,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76032244,"name":"D尧","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p></p> \n<p>美国食品药品监督管理局（FDA）的新药申请(NDA)是药物研发人员向FDA正式提出批准某种新药上市销售的重要环节。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 如果成功的话，只有大约30%或更少的初始候选药物在通过多年的药物研发后最终获得NDA批准。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> </p>\n<p>NDA的目的是提供足够的信息来确保FDA的审查人员能够建立候选药物的完整发展史。申请所需的材料包括:<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> </p> \n<ul>\n <li>专利和生产信息</li> \n <li>按照说明书使用时的药物安全性及其指定用途的特定疗效</li> \n <li>机构审查委员会完成的临床试验设计、合规性和结果报告</li> \n <li>药物滥用的易感性</li> \n <li>指定标签(包装说明书)和使用说明</li>\n</ul> \n<p>这一过程除了某些州选民提出的“药用大麻”的倡议<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup>。 </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221025182750/https://img04.sogoucdn.com/app/a/200698/sogou_science_13374?w=300&h=228&titlename=20%E4%B8%96%E7%BA%AA30%E5%B9%B4%E4%BB%A3%E6%96%B0%E8%8D%AF%E7%A3%BA%E8%83%BA%E5%90%A1%E5%95%B6%E5%9C%A8%E7%BE%8E%E5%9B%BD%E9%A3%9F%E5%93%81%E8%8D%AF%E5%93%81%E7%9B%91%E7%9D%A3%E7%AE%A1%E7%90%86%E5%B1%80%E7%9A%84%E7%94%B3%E8%AF%B7","url":"https://web.archive.org/web/20221025182750/https://img04.sogoucdn.com/app/a/200698/sogou_science_13374","rw":300,"rh":228,"title":"20世纪30年代新药磺胺吡啶在美国食品药品监督管理局的申请","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":null,"versionId":"0","lemmaId":0,"createType":0,"creator":null,"createTime":0,"versionEditor":null,"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":null,"pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":13,"name":"药学","parents":[]}],"creator":{"uid":76033259,"name":"JING","pic":"https://web.archive.org/web/20221025182750/https://cache.soso.com/qlogo/g?b=oidb&k=H2gCqr8SJCBBQ4kJo6dfEw&s=100&t=1572760947","introduction":null,"educations":[{"schoolName":"中国药科大学","major":"","degree":"硕士","universityId":56,"universityLogo":"https://web.archive.org/web/20221025182750/https://img01.sogoucdn.com/app/a/200943/d7fae37e-6011-11e9-ba86-fc4dd4f70029","majorLevel1":"医学","majorLevel2":"中药学","majorLevel3":"中药学","majorLevel1Id":1039,"majorLevel2Id":1296,"majorLevel3Id":1301,"state":null,"lab":null,"researchField":null}],"jobs":null,"works":null,"educationBrief":"中国药科大学","jobBrief":"","role":0,"roleName":null,"title":"中国药科大学 · 中药学硕士","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":17,"partnerIdCreateTime":1594286497,"partnerIdPoped":true},"createTime":1568626582,"editor":{"uid":76032244,"name":"D尧","pic":"https://web.archive.org/web/20221025182750/https://cache.soso.com/qlogo/g?b=oidb&k=Dl7yI7bTMGXoYtLIibLrCow&s=100&t=1556981419","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"state":1,"versionCount":2,"upNum":2,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221025182750/https://img04.sogoucdn.com/app/a/200698/sogou_science_13374?w=300&h=228&titlename=20%E4%B8%96%E7%BA%AA30%E5%B9%B4%E4%BB%A3%E6%96%B0%E8%8D%AF%E7%A3%BA%E8%83%BA%E5%90%A1%E5%95%B6%E5%9C%A8%E7%BE%8E%E5%9B%BD%E9%A3%9F%E5%93%81%E8%8D%AF%E5%93%81%E7%9B%91%E7%9D%A3%E7%AE%A1%E7%90%86%E5%B1%80%E7%9A%84%E7%94%B3%E8%AF%B7","url":"https://web.archive.org/web/20221025182750/https://img04.sogoucdn.com/app/a/200698/sogou_science_13374","rw":300,"rh":228,"title":"20世纪30年代新药磺胺吡啶在美国食品药品监督管理局的申请","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"试验前","paragraphId":"14995430764970260","subCatalogs":null},{"level":1,"title":"临床试验","paragraphId":"14995430764970261","subCatalogs":null},{"level":1,"title":"实际应用","paragraphId":"14995430781747464","subCatalogs":null},{"level":1,"title":"对类似产品的要求","paragraphId":"14995430781747465","subCatalogs":null},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14995430764970260","title":"试验前","versionId":"14995430832079365","lemmaId":10617,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76032244,"name":"D尧","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>在美国，为了对人体受试者进行药物的合法测试，制造商必须首先从FDA获得研究新药（IND）的指示。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> 该申请基于非临床数据，通常来自实验室体内体外相结合的安全性研究，来表明该药物在人体实验中足够安全。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> 提交审批的“新”药物通常包括新分子实体<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>或经过化学修饰产生不同药理作用或减少副作用的原药物。 </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14995430764970261","title":"临床试验","versionId":"14995430832079366","lemmaId":10617,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76032244,"name":"D尧","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>药物批准的法律要求是通过临床对照试验证明药物有效性的“实体”证据。<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup>该标准是药品监管的核心。提交的数据必须来自严格的临床试验。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> </p>\n<p>试验通常分三个阶段进行:<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> </p> \n<ul>\n <li>第一阶段:在20到100名健康志愿者中测试该药物，以确定药物在低剂量下的安全性。大约70%的候选药物进入第二阶段。</li> \n <li>第二阶段:在多达数百名针对该疾病的患者中测试该药物的疗效和安全性。大约三分之二的候选药物由于未达到预期疗效而在第二阶段的临床试验中被淘汰。</li> \n <li>第三阶段:在双盲试验、安慰剂对照试验中，该药物通常在数百至数千名针对该疾病的患者中进行试验，以证明其特定疗效。不到30%的候选药物成功通过第三阶段。</li> \n <li>第四阶段:这些是在数千名服用该药物的人群中进行的药物上市后监测试验，目的是为了监测批准上市药物的药物疗效和安全性。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup></li>\n</ul> \n<p>针对药物安全性和有效性的法律要求被解读为需要科学的证据来证明药物的利大于弊，并且要有详细的使用说明，因为许多药物具有副作用。 </p>\n<p>许多用于治疗严重疾病(例如癌症)的批准药物都有严重甚至危及生命的副作用。即使是相对安全且熟知的非处方药，例如阿司匹林，如果使用不当也会有危险。 </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14995430781747464","title":"实际应用","versionId":"14995430832079367","lemmaId":10617,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76032244,"name":"D尧","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>试验的结果将被编入FDA批准的公共文件，命名为产品标签、包装说明书或完整的处方信息。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 处方信息可以从FDA、药品制造商的网站上获取，<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>并印于药品包装。药品标签的主要目的是为医疗保健提供者提供安全使用该药物的相关信息和指导。 </p>\n<p>NDA要求的文件要能说明药物的全部情况，包括临床试验期间发生的情况、药物配方组成、动物研究结果、药物在体内的作用以及公司制造、加工和包装药物的过程。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>目前，FDA的决策过程缺乏透明度，但是，FDA正在努力使新药的效益风险评估标准化。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup>一旦获得NDA的批准，新药从获批那天起即可在美国合法上市 </p>\n<p>在2009年提交的初始NDA文件中，131份文件中有94份(72%)是eCTD格式。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup> </p>\n<p>一旦提交申请，FDA会进行60天的初步审查，来评估NDA是否“可以通过实质性审查”。如果FDA发现NDA无法通过(理由可以是从申请中的简单行政错误到要求重新进行测试)，那么FDA会向申请人发送拒绝信函拒绝其申请，该信函解释了为何申请不符合要求。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup> </p>\n<p>假设FDA认为可以通过，他们将决定NDA是需要标准审查还是加速审查，并在另一封被称为74天信函的信件中传达对该申请的接受以及他们的审查选择。<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup> 标准审查意味着FDA会在大约10个月内完成，而优先审查会在6个月内完成。<sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup>该决定来自一封完全回应函。 </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14995430781747465","title":"对类似产品的要求","versionId":"14995430832079368","lemmaId":10617,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":76032244,"name":"D尧","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1576233972,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>生物制剂，例如疫苗和许多用于医疗的重组蛋白，通常是由FDA通过生物制品许可申请(BLA)批准，而不是通过NDA批准。生物制剂的生产与简单的化学制剂生产完全不同，批准程序略微不同。 </p>\n<p>由另一制造商通过NDA提交的仿制药通过简略新药申请(ANDA)获得批准，该药不必进行NDA中新药所需的所有临床试验。<sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup> 根据美国现行法律，大多数生物药物，包括大多数的重组蛋白，并不符合ANDA的要求。<sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup>然而，有些生物药物，包括生物合成胰岛素、生长激素、胰高血糖素、降钙素和透明质酸酶，在《联邦食品药品和化妆品法案》的管理下不受限制，因为这些产品在后来《公共卫生服务法案》的生物技术药品法规中已经获得批准。 </p>\n<p>打算用于动物的药物将提交至FDA的另一个中心，即新兽药申请的兽医中心(CVM)。还专门评估了药物在食用动物中的使用以及它们对采用药物治疗的动物进食所产生的影响。 </p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"\"The Drug Development Process\". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"\"The Drug Development Process. Step 4: FDA Drug Review\". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Commissioner, Office of the. \"Public Health Focus - FDA and Marijuana\". www.fda.gov. Archived from the original on April 28, 2018. Retrieved April 30, 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"\"The Drug Development Process. Step 3: Clinical Research\". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"\"The Drug Development Process. Step 1: Discovery and Development\". U.S. Food and Drug Administration. 4 January 2018. Retrieved 1 May 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Food, Drug, and Cosmetic Act, Section 505; 21 USC 355]","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"21 CFR 201.5: Labeling Requirements for Prescription Drugs and/or Insulin","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"\"Daily Med:Current Medication Information\". Archived from the original on November 12, 2008. Retrieved October 10, 2007.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Liberti L, McAuslane JN, Walker S (2011). \"Standardizing the Benefit-Risk Assessment of New Medicines: Practical Applications of Frameworks for the Pharmaceutical Healthcare Professional\". Pharm Med. 25 (3): 139–46. doi:10.1007/BF03256855. Archived from the original on February 6, 2012.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Kathie Clark (December 15, 2009). \"Updates from the Regulators:FDA\". The eCTD summit. Archived from the original on July 16, 2011.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"\"Merck KGaA Receives Refuse To File Letter From FDA On Cladribine Tablets New Drug Application\". medicalnewstoday.com. Archived from the original on March 5, 2010. Retrieved April 30, 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"\"Archived copy\". Archived from the original on March 8, 2010. Retrieved February 23, 2010.CS1 maint: Archived copy as title (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"\"Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance for Treatment of Acute Pain and Fever\". drugs.com. Archived from the original on July 11, 2017. Retrieved April 30, 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"\"FDA, CDER Office of Generic Drugs\". fda.gov. Archived from the original on May 28, 2009. Retrieved April 30, 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"\"C&EN: COVER STORY - BEYOND HATCH-WAXMAN\". pubs.acs.org. Retrieved April 30, 2018.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":158,"auditType":0,"synonyms":null,"showEditTime":"2019.12.13 18:46","auditors":[{"uid":0,"name":"Ki.κe","pic":"https://web.archive.org/web/20221025182750/https://wx.qlogo.cn/mmopen/vi_32/y67kfr32Doib4wg71Jiau7jVWvharic3nRKgdRRQSl6koeQJCo0GQs2Krw0vwdFRsOWnHIQOwAZsSg5lIkIrFCOcQ/132","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false}],"hasZhishiNav":false,"auditInfos":{},"isHistory":false};</script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./617.新药申请 - 搜狗科学百科_files/main_edf0f08.js.download"></script><div id="popControl"><div class="pop-control-mask" style="display: none;"><div class="pop-container"><i class="close-icon"></i><div class="stop-title">搜狗科学百科停止服务运营公告</div><div class="stop-user">亲爱的用户：</div><div class="stop-content">因业务方向调整，搜狗科学百科将于2022年11月11日正式停止服务与运营。届时产品内所有数据将依据相关法律进行删除并关闭服务器，您将无法登录及使用搜狗科学百科，相关内容在平台下线后将无法找回。</div><div class="stop-content">搜狗科学百科是由搜狗推出的科学领域专业百科产品，与搜狗百科为两个独立产品，本次停止服务与运营仅对搜狗科学百科，并不影响搜狗百科产品正常使用，敬请知悉。</div><div class="stop-content">由此给您带来的不便我们深表歉意，敬请谅解。再次感谢您一直以来的陪伴与支持！</div><div class="stop-team">搜狗科学百科产品&amp;运营团队</div><div class="stop-time">2022年10月11日</div></div></div></div>
</body></html>